MedLabs Diagnostics is partnering with a new MedLabs family company, MedLabs Genetics, for its genetic testing. MedLabs Genetics strives to be on the cutting edge of molecular diagnostic technology, using the latest and most accurate methods to bring physicians and patient's confident results.
Testing will include assessment of Thrombophilia risk via genotyping of Factor V, Factor II, and MTHFR 677 & 1298 mutations; assessment of pain management via genotyping of CYP2D6, among others. On the horizon is the largest FDA approved Cystic Fibrosis Mutation panel, which spans 60 gene variants, including the 23 recommended by the American College of Obstetricians and Gynecologists. All testing is performed within a short time of receiving the patient specimen resulting in turnaround times no longer than four days. Services for a genetic counselor will be provided upon request of the patient and/or physician.
Click Here to visit the MedLabs Genetics Website